It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).
160/4.5 mcg BDF single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with current best practice (low certainty).
It is very uncertain whether single component intervention changes adverse events: number of people experiencing adverse events (all… compared with control (very low certainty).
The intervention showed no clear difference in serious adverse events (moderate certainty).
Combination showed no clear difference in overall serious adverse events compared with single‐form nicotine replacement therapy (low certainty).
It is very uncertain whether combinations of antipsychotic drugs changes adverse events: Serious event or requiring discontinuation compared with single antipsychotic drugs (very low certainty).